FDA approves Cornell Dots for first-in-human clinical trial for treatment of cancer
June 14, 2011 in Melanoma news
The U.S. Food and Drug Administration has approved the first clinical trial in humans of a new technology: Cornell Dots, brightly glowing nanoparticles that can light up cancer cells in PET-optical imaging.
Recent melanoma news
- GSK melanoma drug shows promise in early trial - Chicago Tribune
- Phase I Clinical Trial Shows Drug Shrinks Melanoma Brain Metastases - Science Daily (press release)
- GSK melanoma drug shows promise in early trial - Reuters
- GSK melanoma drug shows promise in early trial
- New drug shrinks brain tumours in melanoma patients
- Melanoma Patient Shares Cautionary Tale for Skin Cancer Awareness Month ... - San Francisco Chronicle (press release)
- Phase I Clinical Trial Shows Drug Shrinks Melanoma Brain Metastases